CatalystFDA/Bio

CYTOMX GAINS FAST TRACK STATUS FOR COLORECTAL CANCER ANTIBODY-DRUG CONJUGATE - SEEKINGALPHA

Fast track status accelerates regulatory review for colorectal cancer ADC.

What changed

Fast track status accelerates regulatory review for colorectal cancer ADC.

Why it matters

Fast track status accelerates regulatory review for colorectal cancer ADC. — impact context not separately stored; see What changed.

Sources